199 related articles for article (PubMed ID: 18281730)
21. Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia.
Fowler JA; Bettinger TL; Argo TR
Clin Ther; 2008 Feb; 30(2):231-48. PubMed ID: 18343262
[TBL] [Abstract][Full Text] [Related]
22. Different impacts of aquaporin 4 and MAOA allele variation among olanzapine, risperidone, and paliperidone in schizophrenia.
Chung TS; Lung FW
J Clin Psychopharmacol; 2012 Jun; 32(3):394-7. PubMed ID: 22544010
[TBL] [Abstract][Full Text] [Related]
23. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.
Li H; Rui Q; Ning X; Xu H; Gu N
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):1002-8. PubMed ID: 21315787
[TBL] [Abstract][Full Text] [Related]
24. Effects of acute paliperidone palmitate treatment in subjects with schizophrenia recently treated with oral risperidone.
Sliwa JK; Bossie CA; Ma YW; Alphs L
Schizophr Res; 2011 Oct; 132(1):28-34. PubMed ID: 21775106
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and tolerability of paliperidone ER and other oral atypical antipsychotics in schizophrenia.
Jones MP; Nicholl D; Trakas K
Int J Clin Pharmacol Ther; 2010 Jun; 48(6):383-99. PubMed ID: 20497747
[TBL] [Abstract][Full Text] [Related]
26. Obsessive-compulsive symptoms induced by long-acting injectable paliperidone in a patient with schizophrenia: a case report.
Vázquez-Bourgon J; Rodríguez-Rodríguez P; Gómez-Ruíz E; Artal J; Crespo-Facorro B
Ann Clin Psychiatry; 2014 Nov; 26(4):301-2. PubMed ID: 25401718
[No Abstract] [Full Text] [Related]
27. Expected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release.
Pani L; Marchese G
Expert Opin Drug Deliv; 2009 Mar; 6(3):319-31. PubMed ID: 19317589
[TBL] [Abstract][Full Text] [Related]
28. [Guidelines for the use of second-generation long-acting antipsychotics].
Jarema M; Wichniak A; Dudek D; Samochowiec J; Bieńkowski P; Rybakowski J
Psychiatr Pol; 2015; 49(2):225-41. PubMed ID: 26093588
[TBL] [Abstract][Full Text] [Related]
29. Paliperidone palmitate for schizophrenia.
Nussbaum AM; Stroup TS
Cochrane Database Syst Rev; 2012 Jun; (6):CD008296. PubMed ID: 22696377
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of long acting injectable atypical antipsychotics: a review.
De Berardis D; Marini S; Carano A; Lang AP; Cavuto M; Piersanti M; Fornaro M; Perna G; Valchera A; Mazza M; Iasevoli F; Martinotti G; Di Giannantonio M
Curr Clin Pharmacol; 2013 Aug; 8(3):256-64. PubMed ID: 23343445
[TBL] [Abstract][Full Text] [Related]
31. Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial.
Takekita Y; Koshikawa Y; Fabbri C; Sakai S; Sunada N; Onohara A; Nishida K; Yoshimura M; Kato M; Serretti A; Kinoshita T
BMC Psychiatry; 2016 May; 16():172. PubMed ID: 27236412
[TBL] [Abstract][Full Text] [Related]
32. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study.
Davidson M; Emsley R; Kramer M; Ford L; Pan G; Lim P; Eerdekens M
Schizophr Res; 2007 Jul; 93(1-3):117-30. PubMed ID: 17466492
[TBL] [Abstract][Full Text] [Related]
33. Mortality rate is associated with paliperidone palmitate, risperidone long-acting injection, and oral paliperidone administration.
Suzuki H; Hibino H; Inoue Y; Takaya A
Asian J Psychiatr; 2018 Jun; 35():28. PubMed ID: 29751217
[No Abstract] [Full Text] [Related]
34. Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly, long-acting formulation of an atypical antipsychotic.
Samtani MN; Vermeulen A; Stuyckens K
Clin Pharmacokinet; 2009; 48(9):585-600. PubMed ID: 19725593
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of paliperidone extended-release in schizophrenia patients with prominent affective symptoms.
Canuso CM; Turkoz I; Sheehan JJ; Bossie CA
J Affect Disord; 2010 Jan; 120(1-3):193-9. PubMed ID: 19552963
[TBL] [Abstract][Full Text] [Related]
36. In brief: Injectable paliperidone palmitate for schizophrenia.
Med Lett Drugs Ther; 2009 Nov; 51(1324):88. PubMed ID: 19890247
[No Abstract] [Full Text] [Related]
37. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
[TBL] [Abstract][Full Text] [Related]
38. Serum concentrations of paliperidone versus risperidone and clinical effects.
Nazirizadeh Y; Vogel F; Bader W; Haen E; Pfuhlmann B; Gründer G; Paulzen M; Schwarz M; Zernig G; Hiemke C
Eur J Clin Pharmacol; 2010 Aug; 66(8):797-803. PubMed ID: 20358189
[TBL] [Abstract][Full Text] [Related]
39. Paliperidone for schizophrenia.
Nussbaum A; Stroup TS
Cochrane Database Syst Rev; 2008 Apr; (2):CD006369. PubMed ID: 18425951
[TBL] [Abstract][Full Text] [Related]
40. Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study.
Kane JM; D'Souza DC; Patkar AA; Youakim JM; Tiller JM; Yang R; Keefe RS
J Clin Psychiatry; 2010 Nov; 71(11):1475-81. PubMed ID: 20816042
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
